Benchling: Business Overview, Financials & Competitive Analysis
Benchling scores 8/10 on the AskCyborg Cyborg Score (Strong). Well-capitalized life sciences software leader capturing high-growth synthetic biology market with strategic acquisitions and expanding platform capabilities. Benchling is a series F company founded in 2012 with $412M in funding and a current valuation of $6.1B. The company's most recent deal was a merger/acquisition with Sphinx Bio on August 20, 2025.
What is Benchling's industry? Benchling (benchling.com) operates in Life Sciences Tools and Services. AskCyborg classifies Benchling under Life Sciences Tools and Services in its company registry.
Benchling is a developer of a lab collaboration platform designed to make life science research quick and collaborative, with a platform specializing in offering a suite of natively unified applications that accelerat...
Cyborg Score thesis
Well-capitalized life sciences software leader capturing high-growth synthetic biology market with strategic acquisitions and...
Read the full analyst-debate transcript →Get the Latest Benchling Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBenchling Overview
Pro stress-test →Benchling is a developer of a lab collaboration platform designed to make life science research quick and collaborative, with a platform specializing in offering a suite of natively unified applications that accelerate research and development at all levels, where scientists can design, share, and record experiments as well as share DNA-sequence data in the cloud. The platform enables researchers to accelerate, measure, and forecast research and development from discovery to bioprocessing in one integrated environment.
Strategic Profile
Pro stress-test →Benchling was founded in 2012 in San Francisco, California by Sajith Wickramasekara and Ashu Singhal, with the mission to accelerate life sciences research and unlock the power of biotechnology. The global synthetic biology market is expected to reach $30.7 billion by 2026, growing at a CAGR of 26.3%, positioning Benchling at the center of a high-growth market for biology software infrastructure.
Competitive Landscape
Pro stress-test →Benchling's competitors include DNA Script, DNAnexus, Genedata, Genuity Science, and BenchSci. Benchling maintains a differentiated position through its unified cloud platform spanning design, execution, and analysis, with particular strength in synthetic biology workflows and CRISPR tools. The competitive landscape includes both specialized point solutions and broader ELN/LIMS platforms.
Industry Context
Benchling operates in Life Sciences Tools and Services.
Key facts
Founded: 2012 · Headquarters: San Francisco, US · Employees: 797 · Market cap: $6.1B